Copy to clipboard 
Smith+Nephew reported 4Q21 orthopedic sales of $947.4 million, +0.9% vs. 4Q20. For the full year, the company generated $3.6 billion in orthopedic sales, +14.1% vs. 2020. Compared to 2019, Smith+Nephew declined -0.5% in 2021.
Despite nearly regaining its pre-pandemic revenue levels, Smith+Nephew exited 2021 with a multitude of challenges. Until recently, the company lacked cementless knee products and lost market share to competitors. Compared to 2019, Smith+Nephew’s knee replacement sales declined more than -13%.
The company’s hip franchise softened in the second half of 2021 due to internal supply chain problems and volume-based procurement pressures in China. Smith+Nephew mitigated some of the price declines in China through negotiation with distributors and a simplified go-to-market strategy.
The internal supply chain issues have improved, but have not been completely resolved. Smith+Nephew CFO Anne-Francoise Nesmes said, “Memphis has stabilized. We’ve done a lot of work internally around our sales and operation planning. There’s more to come. I’m not going to say it’s all resolved. There’s more work to do to make sure our network is resilient. But we are in a much more stable situation on that front.”
Smith+Nephew opted for new leadership to restore the company’s momentum. It tapped Dr. Deepak Nath as its new Chief Executive Officer, succeeding Roland Diggelmann, who will step down by mutual agreement with the Board of Directors. Dr. Nath takes on his new role in April 2022.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $425.3 | $428.4 | ($3.1) | (0.7%) |
| Knees | $257.0 | $253.0 | $4.0 | 1.6% |
| Hips | $151.0 | $162.0 | ($11.0) | (6.8%) |
| Extremities | $17.3 | $13.4 | $3.9 | 29.1% |
| Trauma | $126.7 | $116.6 | $10.1 | 8.7% |
| Sports Medicine | $380.0 | $381.0 | ($1.0) | (0.3%) |
| Orthobiologics | $15.4 | $12.8 | $2.6 | 19.9% |
| Total | $947.4 | $938.8 | $8.6 | 0.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,648.4 | $1,506.0 | $142.4 | 9.5% |
| Knees | $968.0 | $890.5 | $77.5 | 8.7% |
| Hips | $611.0 | $567.6 | $43.4 | 7.6% |
| Extremities | $69.4 | $47.8 | $21.5 | 45% |
| Trauma | $508.6 | $412.3 | $96.4 | 23.4% |
| Sports Medicine | $1,428.0 | $1,226.3 | $201.8 | 16.5% |
| Orthobiologics | $59.6 | $49.9 | $9.7 | 19.4% |
| Total | $3,644.6 | $3,194.4 | $450.2 | 14.1% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $498.3 | $487.8 | $10.5 | 2.2% |
| OUS | $449.0 | $451.0 | ($2.0) | (0.4%) |
| EMEA | $244.7 | $255.8 | ($11.1) | (4.3%) |
| Asia Pacific | $109.4 | $105.1 | $4.2 | 4% |
| Rest of World | $95.0 | $90.1 | $4.9 | 5.4% |
| Total | $947.4 | $938.8 | $8.5 | 0.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $1,859.3 | $1,639.8 | $219.5 | 13.4% |
| OUS | $1,785.4 | $1,554.7 | $230.7 | 14.8% |
| EMEA | $972.6 | $863.8 | $108.9 | 12.6% |
| Asia Pacific | $435.0 | $370.9 | $64.1 | 17.3% |
| Rest of World | $377.8 | $320.0 | $57.7 | 18% |
| Total | $3,644.6 | $3,194.4 | $450.2 | 14.1% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Smith+Nephew reported 4Q21 orthopedic sales of $947.4 million, +0.9% vs. 4Q20. For the full year, the company generated $3.6 billion in orthopedic sales, +14.1% vs. 2020. Compared to 2019, Smith+Nephew declined -0.5% in 2021.
Despite nearly regaining its pre-pandemic revenue levels, Smith+Nephew exited 2021 with a multitude of challenges....
Smith+Nephew reported 4Q21 orthopedic sales of $947.4 million, +0.9% vs. 4Q20. For the full year, the company generated $3.6 billion in orthopedic sales, +14.1% vs. 2020. Compared to 2019, Smith+Nephew declined -0.5% in 2021.
Despite nearly regaining its pre-pandemic revenue levels, Smith+Nephew exited 2021 with a multitude of challenges. Until recently, the company lacked cementless knee products and lost market share to competitors. Compared to 2019, Smith+Nephew’s knee replacement sales declined more than -13%.
The company’s hip franchise softened in the second half of 2021 due to internal supply chain problems and volume-based procurement pressures in China. Smith+Nephew mitigated some of the price declines in China through negotiation with distributors and a simplified go-to-market strategy.
The internal supply chain issues have improved, but have not been completely resolved. Smith+Nephew CFO Anne-Francoise Nesmes said, “Memphis has stabilized. We’ve done a lot of work internally around our sales and operation planning. There’s more to come. I’m not going to say it’s all resolved. There’s more work to do to make sure our network is resilient. But we are in a much more stable situation on that front.”
Smith+Nephew opted for new leadership to restore the company’s momentum. It tapped Dr. Deepak Nath as its new Chief Executive Officer, succeeding Roland Diggelmann, who will step down by mutual agreement with the Board of Directors. Dr. Nath takes on his new role in April 2022.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $425.3 | $428.4 | ($3.1) | (0.7%) |
| Knees | $257.0 | $253.0 | $4.0 | 1.6% |
| Hips | $151.0 | $162.0 | ($11.0) | (6.8%) |
| Extremities | $17.3 | $13.4 | $3.9 | 29.1% |
| Trauma | $126.7 | $116.6 | $10.1 | 8.7% |
| Sports Medicine | $380.0 | $381.0 | ($1.0) | (0.3%) |
| Orthobiologics | $15.4 | $12.8 | $2.6 | 19.9% |
| Total | $947.4 | $938.8 | $8.6 | 0.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,648.4 | $1,506.0 | $142.4 | 9.5% |
| Knees | $968.0 | $890.5 | $77.5 | 8.7% |
| Hips | $611.0 | $567.6 | $43.4 | 7.6% |
| Extremities | $69.4 | $47.8 | $21.5 | 45% |
| Trauma | $508.6 | $412.3 | $96.4 | 23.4% |
| Sports Medicine | $1,428.0 | $1,226.3 | $201.8 | 16.5% |
| Orthobiologics | $59.6 | $49.9 | $9.7 | 19.4% |
| Total | $3,644.6 | $3,194.4 | $450.2 | 14.1% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $498.3 | $487.8 | $10.5 | 2.2% |
| OUS | $449.0 | $451.0 | ($2.0) | (0.4%) |
| EMEA | $244.7 | $255.8 | ($11.1) | (4.3%) |
| Asia Pacific | $109.4 | $105.1 | $4.2 | 4% |
| Rest of World | $95.0 | $90.1 | $4.9 | 5.4% |
| Total | $947.4 | $938.8 | $8.5 | 0.9% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $1,859.3 | $1,639.8 | $219.5 | 13.4% |
| OUS | $1,785.4 | $1,554.7 | $230.7 | 14.8% |
| EMEA | $972.6 | $863.8 | $108.9 | 12.6% |
| Asia Pacific | $435.0 | $370.9 | $64.1 | 17.3% |
| Rest of World | $377.8 | $320.0 | $57.7 | 18% |
| Total | $3,644.6 | $3,194.4 | $450.2 | 14.1% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
